Skip to main content
SpringerLink
Log in

Impact of cancer cachexia

  • Chapter
  • First Online:
Cancer Cachexia

  • 443 Accesses

Abstract

Cachexia is a common complication in cancer and, unfortunately, individuals with cachexia are less able to tolerate anti-tumor therapy and have poor survival rates. For example, lung cancer is the second leading cause of new cancer cases in the United States, with an estimated 226,160 patients diagnosed in 2012 alone, about half of which will suffer from involuntary weight loss.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Dewys WD, Begg C, Lavin PT, et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med. 1980;69:491-497.

    Google Scholar 

  2. Chochinov HM, Hack T, Hassard T, Kristjanson LJ, McClement S, Harlos M. Dignity in the terminally ill a cross-sectional, cohort study. Lancet. 2002;360:2026-2030.

    Google Scholar 

  3. Lasheen W, Walsh D. The cancer anorexia-cachexia syndrome: myth or reality? Support Care Cancer. 2010;18:265-272.

    Google Scholar 

  4. McNeely ML, Courneya KS. Exercise programs for cancer-related fatigue: evidence and clinical guidelines. J Natl Compr Canc Netw. 2010;8:945-953.

    Google Scholar 

  5. Bruera E, Valero V, Driver L, et al. Patient-controlled methylphenidate for cancer fatigue: a double-blind, randomized, placebo-controlled trial. J Clin Oncol. 2006;24:2073-2078.

    Google Scholar 

  6. Stephens NA, Gray C, Macdonald AJ, et al. Sexual dimorphism modulates the impact of cancer cachexia on lower limb muscle mass and function. Clin Nutr. 2012; [Epub ahead of print].

    Google Scholar 

  7. Rees E, Hardy J, Ling J, Broadley K, A’Hern R. The use of the Edmonton Symptom Assessment Scale (ESAS) within a palliative care unit in the UK. Palliat Med. 1998;12:75-82.

    Google Scholar 

  8. Bauer J, Capra S, Ferguson M. Use of the scored Patient-Generated Subjective Global Assessment (PG-SGA) as a nutrition assessment tool in patients with cancer. Eur J Clin Nutr. 2002;56:779-785.

    Google Scholar 

  9. Yavuzsen T, Walsh D, Davis MP, et al. Components of the anorexia-cachexia syndrome: gastrointestinal symptom correlates of cancer anorexia. Support Care Cancer. 2009;17:1531-1541.

    Google Scholar 

  10. Del Fabbro E, Hui D, Dalal S, Dev R, Nooruddin ZI, Bruera E. Clinical outcomes and contributors to weight loss in a cancer cachexia clinic. J Palliat Med. 2011;14:1004-1008.

    Google Scholar 

  11. Rajagopal A, Vassilopoulou-Sellin R, Palmer JL, Kaur G, Bruera E. Symptomatic hypogonadism in male survivors of cancer with chronic exposure to opioids. Cancer. 2004;100:851-858.

    Google Scholar 

  12. Rini BI, Tamaskar I, Shaheen P, et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst. 2007;99:81-83.

    Google Scholar 

  13. Antoun S, Birdsell L, Sawyer MB, Venner P, Escudier B, Baracos VE. Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study. J Clin Oncol. 2010;28:1054-1060.

    Google Scholar 

  14. Nelson K, Walsh D, Sheehan F. Cancer and chemotherapy-related upper gastrointestinal symptoms: the role of abnormal gastric motor function and its evaluation in cancer patients. Support Care Cancer. 2002;10:455-461.

    Google Scholar 

  15. Donthireddy KR, Ailawadhi S, Nasser E, et al. Malignant gastroparesis: pathogenesis and management of an underrecognized disorder. J Support Oncol. 2007;5:355-363.

    Google Scholar 

  16. Davis M. Early Satiety. In: Del Fabbro E, Barakos V, Wahnefried WD, Bowling T, Hopkinson J, Bruera E, eds. Nutrition and the Cancer Patient. 1st ed. New York: Oxford University Press 2010:189-200.

    Google Scholar 

  17. Patrick A, Epstein O. Review article: gastroparesis. Aliment Pharmacol Ther. 2008;27:724-740.

    Google Scholar 

  18. Shivshanker K, Bennett RW, Jr., Haynie TP. Tumor-associated gastroparesis: correction with metoclopramide. Am J Surg. 1983;145:221-225.

    Google Scholar 

  19. Nelson KA, Walsh TD, Sheehan FG, O’Donovan PB, Falk GW. Assessment of upper gastrointestinal motility in the cancer-associated dyspepsia syndrome. J Palliat Care. 1993;9:27-31.

    Google Scholar 

  20. Boivin MA, Carey MC, Levy H. Erythromycin accelerates gastric emptying in a dose-response manner in healthy subjects. Pharmacotherapy. 2003;23:5-8.

    Google Scholar 

  21. Davis M, Lasheen W, Walsh D, Mahmoud F, Bicanovsky L, Lagman R. A Phase II dose titration study of thalidomide for cancer-associated anorexia. J Pain Symptom Manage. 2012;43:78-86.

    Google Scholar 

  22. Sturm A, Holtmann G, Goebell H, Gerken G. Prokinetics in patients with gastroparesis: a systematic analysis. Digestion. 1999;60:422-427.

    Google Scholar 

  23. McClement SE. Involuntary weight loss and altered body image in patients with cancer anorexia-cachexia syndrome. In: Del Fabbro E, Baracos V, Demark-Wahnefried W, Bowling T, Hopkinson J, Bruera E, (Eds.). Nutrition and the Cancer Patient. New York: Oxford University Press; 2010:499-508.

    Google Scholar 

  24. Fredrix EW, Soeters PB, Wouters EF, Deerenberg IM, von Meyenfeldt MF, Saris WH. Effect of different tumor types on resting energy expenditure. Cancer Res. 1991;51:6138-6141.

    Google Scholar 

  25. Dempsey DT, Feurer ID, Knox LS, Crosby LO, Buzby GP, Mullen JL. Energy expenditure in malnourished gastrointestinal cancer patients. Cancer. 1984;53:1265-1273.

    Google Scholar 

  26. Vaisman N, Lusthaus M, Niv E, et al. Effect of tumor load on energy expenditure in patients with pancreatic cancer. Pancreas. 2012;41:230-232.

    Google Scholar 

  27. Lugli AK, Donatelli F, Schricker T, Wykes L, Carli F. Preoperative glucose and protein metabolism: the influence of diabetes mellitus type 2 in patients with colorectal tumors. Nutr Cancer. 2011;63:924-929.

    Google Scholar 

  28. Hyltander A, Daneryd P, Sandstrom R, Korner U, Lundholm K. Beta-adrenoceptor activity and resting energy metabolism in weight losing cancer patients. Eur J Cancer. 2000;36:330-334.

    Google Scholar 

  29. Reeves MM, Capra S. Predicting energy requirements in the clinical setting: are current methods evidence based? Nutr Rev. 2003;61:143-151.

    Google Scholar 

  30. Barak N, Wall-Alonso E, Sitrin MD.Evaluation of stress factors and body weight adjustments currently used to estimate energy expenditure in hospitalized patients. J Parenter Enteral Nutr. 2002;26:231-238.

    Google Scholar 

  31. Herndon JE, 2nd, Fleishman S, Kornblith AB, Kosty M, Green MR, Holland J. Is quality of life predictive of the survival of patients with advanced nonsmall cell lung carcinoma? Cancer. 1999;85:333-340.

    Google Scholar 

  32. Davidson W, Ash S, Capra S, Bauer J. Weight stabilisation is associated with improved survival duration and quality of life in unresectable pancreatic cancer. Clin Nutr. 2004;23:239-247.

    Google Scholar 

  33. Maltoni M, Nanni O, Scarpi E, Rossi D, Serra P, Amadori D. High-dose progestins for the treatment of cancer anorexia-cachexia syndrome: a systematic review of randomised clinical trials. Ann Oncol. 2001;12:289-300.

    Google Scholar 

  34. Ruiz-Garcia V, Juan O, Perez Hoyos S, et al. [Megestrol acetate: a systematic review usefulness about the weight gain in neoplastic patients with cachexia]. Med Clin (Barc). 2002;119:166-170.

    Google Scholar 

  35. Pascual Lopez A, Roque i Figuls M, Urrutia Cuchi G, et al. Systematic review of megestrol acetate in the treatment of anorexia-cachexia syndrome. J Pain Symptom Manage. 2004;27:360-369.

    Google Scholar 

  36. Berenstein EG, Ortiz Z. Megestrol acetate for the treatment of anorexia-cachexia syndrome. Cochrane Database Syst Rev. 2005:CD004310.

    Google Scholar 

  37. Lesniak W, Bala M, Jaeschke R, Krzakowski M. Effects of megestrol acetate in patients with cancer anorexia-cachexia syndrome–a systematic review and meta-analysis. Pol Arch Med Wewn. 2008;118:636-644.

    Google Scholar 

  38. Webster K, Cella D, Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation. Health Qual Life Outcomes. 2003;1:79.

    Google Scholar 

  39. Lent L, Hahn E, Eremenco S, Webster K, Cella D. Using cross-cultural input to adapt the Functional Assessment of Chronic Illness Therapy (FACIT) scales. Acta Oncol. 1999;38:695-702.

    Google Scholar 

  40. Ribaudo JM, Cella D, Hahn EA, et al. Re-validation and shortening of the Functional Assessment of Anorexia/Cachexia Therapy (FAACT) questionnaire. Qual Life Res. 2000;9:1137-1146.

    Google Scholar 

  41. Guyatt GH, Osoba D, Wu AW, Wyrwich KW, Norman GR. Methods to explain the clinical significance of health status measures. Mayo Clin Proc. 2002;77:371-383.

    Google Scholar 

  42. Lai JS, Cella D, Peterman A, Barocas J, Goldman S. Anorexia/cachexia-related quality of life of children with cancer. Cancer. 2005;104:1531-1539.

    Google Scholar 

  43. Robinson Jr DW, Eisenberg DF, Cella D, Zhao N, de Boer C, DeWitte M. The prognostic significance of patient-reported outcomes in pancreatic cancer cachexia. J Support Oncol. 2008;6:283-290.

    Google Scholar 

  44. Dahele M, Skipworth RJ, Wall L, Voss A, Preston T, Fearon KC. Objective physical activity and self-reported quality of life in patients receiving palliative chemotherapy. J Pain Symptom Manage. 2007;33:676-685.

    Google Scholar 

  45. Efficace F, Bottomley A, Smit EF, et al. Is a patient’s self-reported health-related quality of life a prognostic factor for survival in non-small-cell lung cancer patients? A multivariate analysis of prognostic factors of EORTC study 08975. Ann Oncol. 2006;17:1698-1704.

    Google Scholar 

  46. Quinten C, Coens C, Mauer M, et al. Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials. Lancet Oncol. 2009;10:865-871.

    Google Scholar 

  47. DeWys WD, Begg C, Lavin PT, et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med. 1980;69:491-497.

    Google Scholar 

  48. Andreyev HJ, Norman AR, Oates J, Cunningham D. Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? Eur J Cancer. 1998;34:503-509.

    Google Scholar 

  49. Ross PJ, Ashley S, Norton A, et al. Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers? Br J Cancer. 2004;90:1905-1911.

    Google Scholar 

  50. Hauser CA, Stockler MR, Tattersall MH. Prognostic factors in patients with recently diagnosed incurable cancer: a systematic review. Support Care Cancer. 2006;14:999-1011.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA

    Egidio Del Fabbro

  2. Psychosomatic Internal Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Kagoshima, Japan

    Akio Inui

  3. Department of Internal Medicine, Cantonal Hospital, St Gallen, St. Gallen, Switzerland

    Florian Strasser

Authors
  1. Egidio Del Fabbro
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Akio Inui
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Florian Strasser
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Egidio Del Fabbro .

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Healthcare

About this chapter

Cite this chapter

Del Fabbro, E., Inui, A., Strasser, F. (2012). Impact of cancer cachexia. In: Cancer Cachexia. Springer Healthcare, Tarporley. https://doi.org/10.1007/978-1-910315-07-1_3

Download citation

  • DOI: https://doi.org/10.1007/978-1-910315-07-1_3

  • Published:

  • Publisher Name: Springer Healthcare, Tarporley

  • Print ISBN: 978-1-910315-06-4

  • Online ISBN: 978-1-910315-07-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation